Ascendis Health Limited (JSE: ASC)
South Africa
· Delayed Price · Currency is ZAR
90.00
+12.00 (15.38%)
Dec 20, 2024, 5:00 PM SAST
Ascendis Health Revenue
In the fiscal year ending June 30, 2024, Ascendis Health had annual revenue of 1.47B ZAR, down -4.13%. Ascendis Health had revenue of 734.49M in the half year ending June 30, 2024, a decrease of -6.05%.
Revenue
1.47B
Revenue Growth
-4.13%
P/S Ratio
0.38
Revenue / Employee
105.15M
Employees
14
Market Cap
563.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 1.47B | -63.39M | -4.13% |
Jun 30, 2023 | 1.54B | -24.02M | -1.54% |
Jun 30, 2022 | 1.56B | -266.01M | -14.57% |
Jun 30, 2021 | 1.83B | -377.56M | -17.14% |
Jun 30, 2020 | 2.20B | -3.67B | -62.48% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAscendis Health News
- 6 weeks ago - Novo Nordisk, Ascendis partner to advance once-monthly obesity drug candidate - Seeking Alpha
- 3 months ago - Ascendis Challenges BioMarin, But Market Response Seems Excessive - Seeking Alpha
- 3 months ago - Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term - Benzinga
- 3 months ago - BioMarin off 17% as Ascendis data seen as threat to Voxzogo - Seeking Alpha
- 3 months ago - Ascendis gets FDA orphan drug status for Yorvipath for hypothyroidism - Seeking Alpha
- 3 months ago - Ascendis raised to outperform by Oppenheimer ahead of drug launch - Seeking Alpha
- 3 months ago - Ascendis stock falls 12% amid lowered outlook, royalty deal - Seeking Alpha
- 3 months ago - Ascendis and Royalty Pharma enter into $150M royalty funding agreement - Seeking Alpha